S
75.89
5.89 (8.41%)
| 前收盘价格 | 70.00 |
| 收盘价格 | 72.50 |
| 成交量 | 17,725 |
| 平均成交量 (3个月) | 41,373 |
| 市值 | 246,283,616 |
| 价格/销量 (P/S) | 10.75 |
| 股市价格/股市净资产 (P/B) | 10.65 |
| 52周波幅 | |
| 利润日期 | 1 May 2026 |
| 营业毛利率 | -107.77% |
| 营业利益率 (TTM) | -879.63% |
| 稀释每股收益 (EPS TTM) | -4.70 |
| 季度收入增长率 (YOY) | 121.20% |
| 总债务/股东权益 (D/E MRQ) | 5.84% |
| 流动比率 (MRQ) | 5.12 |
| 营业现金流 (OCF TTM) | -13.89 M |
| 杠杆自由现金流 (LFCF TTM) | -9.91 M |
| 资产报酬率 (ROA TTM) | -26.82% |
| 股东权益报酬率 (ROE TTM) | -49.39% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Sol-Gel Technologies Ltd. | 看涨 | 看涨 |
AIStockmoo 评分
-0.1
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.13 |
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 70.00% |
| 机构持股比例 | 24.29% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合